CoChat

Effects of semaglutide on beta cell function and glycaemic control in participants with type 2 diabetes: a randomised, double-blind, placebo-controlled trial

Open access
Kapitza, Christoph, Dahl, Kirsten, Jacobsen, Jacob B., Axelsen, Mads B., Flint, Anne · 2017 · Diabetologia
Cited by 117

The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.

Abstract

Semaglutide is a glucagon-like peptide-1 analogue in development for the treatment of type 2 diabetes. Its effects on first- and second-phase insulin secretion and other measures of beta cell function and glycaemic control were assessed. In this single-centre, double-blind, placebo-controlled, parallel-group trial, conducted at the Profil Institut für Stoffwechselforschung, Germany, 75 adult (aged 18–64 years) participants with type 2 diabetes (eligibility: HbA1c of 6.5–9.0% (47.5–74.9 mmol/mol); BMI 20.0–35.0 kg/m2; and treatment with diet and exercise and/or metformin monotherapy with a dose unchanged in the 30 days prior to screening) were randomised (1:1) to once-weekly s.c. semaglutide 1.0 mg (0.25, 0.5, 1.0 mg escalated) or placebo for 12 weeks. Co-primary endpoints were changes from baseline to end of treatment in the first (AUC0–10 min) and second (AUC10–120 min) insulin secretion phases, as measured by the IVGTT. An arginine stimulation test (AST) and a 24 h meal stimulation test were also conducted. A graded glucose infusion test (GGIT) assessed insulin secretion rate (ISR) in treated participants and a group of untreated healthy participants. Safety endpoints were also assessed. In total, 37 participants received semaglutide and 38 received placebo. Following IVGTT, for insulin, both AUC0−10min and AUC10−120min were significantly increased with semaglutide (estimated treatment ratio [95% CI] 3.02 [2.53, 3.60] and 2.10 [1.86, 2.37], respectively; p < 0.0001). The 24 h meal test showed reduced fasting, postprandial and overall (AUC0–24h) glucose and glucagon responses with semaglutide (p < 0.0001). The AST showed that maximal insulin capacity increased following semaglutide treatment. During GGIT, semaglutide significantly increased ISR to levels similar to those in healthy participants. Semaglutide was well tolerated. Twelve weeks of once-weekly treatment with semaglutide significantly improved beta cell function and glycaemic control in participants with type 2 diabetes. ClinicalTrials.gov NCT02212067 The study was funded by Novo Nordisk A/S.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s00125-017-4289-0

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 25 references

Research works printed but not linked: 17

  1. Kondo Y, Satoh S, Osada UN, Terauchi Y (2015) Early liraglutide treatment improves beta-cell function in patients with type 2 diabetes: a retrospective cohort study. Endocr J 62:971–980 · DOI
  2. Chang AM, Jakobsen G, Sturis J et al (2003) The GLP-1 derivative NN2211 restores beta-cell sensitivity to glucose in type 2 diabetic patients after a single dose. Diabetes 52:1786–1791 · DOI · Paper page
  3. European Agency for the Evaluation of Medicinal Products. International Conference on Harmonisation—World Health Organization Guideline for good clinical practice ICH Harmonised tripartite guideline good clinical practice www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002874.pdf . Accessed 10 February 2017
  4. Van Cauter E, Mestrez F, Sturis J, Polonsky KS (1992) Estimation of insulin secretion rates from C-peptide levels. Comparison of individual and standard kinetic parameters for C-peptide clearance. Diabetes 41:368–377 · DOI
  5. Hovorka R, Soons PA, Young MA (1996) ISEC: a program to calculate insulin secretion. Comput Methods Prog Biomed 50:253–264 · DOI · Paper page
  6. Kozawa J, Inoue K, Iwamoto R et al (2012) Liraglutide is effective in type 2 diabetic patients with sustained endogenous insulin-secreting capacity. J Diabetes Investig 3:294–297 · DOI
  7. American Diabetes Association (2016) Standards of medical care in diabetes-2016 abridged for primary care providers. Clin Diabetes 34:3–21 · DOI · Paper page
  8. Ho TP, Zhao X, Courville AB et al (2015) Effects of a 12-month moderate weight loss intervention on insulin sensitivity and inflammation status in nondiabetic overweight and obese subjects. Horm Metab Res 47:289–296
  9. Murakata Y, Fujimaki T, Yamada Y (2015) Age-related changes in clinical parameters and their associations with common complex diseases. Biomed Rep 3:767–777 · DOI
  10. De Tata V (2014) Age-related impairment of pancreatic Beta-cell function: pathophysiological and cellular mechanisms. Front Endocrinol (Lausanne) 5:138 · DOI · Paper page
  11. Standl E (2007) The importance of beta-cell management in type 2 diabetes. Int J Clin Pract 61(Suppl 153):10–19 · DOI
  12. Zheng J, Chen T, Zhu Y et al (2015) Liraglutide prevents fast weight gain and beta-cell dysfunction in male catch-up growth rats. Exp Biol Med (Maywood) 240:1165–1176 · DOI
  13. Tudurí E, López M, Diéguez C, Nadal A, Nogueiras R (2016) Glucagon-like peptide 1 analogs and their effects on pancreatic islets. Trends Endocrinol Metab 27:304–318 · DOI
  14. Ahmann AJ, Capehorn M, Charpentier G et al (2016) Efficacy and safety of once-weekly semaglutide vs exenatide ER after 56 weeks in subjects with type 2 diabetes (SUSTAIN 3). Diabetologia 59:S76 (Abstract) · DOI
  15. Madsbad S (2016) Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists. Diabetes Obes Metab 18:317–332 · DOI · Paper page
  16. Madsbad S, Kielgast U, Asmar M, Deacon CF, Torekov SS, Holst JJ (2011) An overview of once-weekly glucagon-like peptide-1 receptor agonists—available efficacy and safety data and perspectives for the future. Diabetes Obes Metab 13:394–407 · DOI · Paper page
  17. Marre M, Shaw J, Brändle M et al (2009) Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU). Diabet Med 26:268–278 · DOI · Paper page

Cited by

See all 117

Metadata

Authors
Kapitza, C., Dahl, K., Jacobsen, J. B., Axelsen, M. B., & Flint, A.
Venue
Diabetologia
Published
2017-05-19
Volume
60
Issue
8
Pages
1390-1399
ISSN
  • 0012-186X (ISSN-L)
  • 1432-0428
OpenAlex
W2614548128
Cited by
117
References
25
FWCI
6.31
Type
journal article
Language
en
Open access
hybrid
Funders
Novo Nordisk A/S

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effects of semaglutide on beta cell function and glycaemic control in participants with type 2 diabetes: a randomised, double-blind, placebo-controlled trial. https://app.cochat.ai/papers/10.1007/s00125-017-4289-0
The paper
Kapitza, C., Dahl, K., Jacobsen, J. B., Axelsen, M. B., & Flint, A. (2017). Effects of semaglutide on beta cell function and glycaemic control in participants with type 2 diabetes: a randomised, double-blind, placebo-controlled trial. Diabetologia. https://doi.org/10.1007/s00125-017-4289-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.